Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation

Discussion explores how combining complementary payload technologies may unlock new therapeutic opportunities while reinforcing the versatility of Akari's proprietary PH1 spliceosome-modulating payload platform

TAMPA, Fla. and LONDON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today released a new CEO Corner segment featuring President and Chief Executive Officer Abizer Gaslightwala discussing the Company's recently announced strategic research collaboration with WhiteHawk Therapeutics and why the Company believes scientifically driven collaborations will play an increasingly important role in advancing the next generation of ADC innovation.